Syncromune, Inc.
- Biotech or pharma, therapeutic R&D
Syncromune, Inc. is developing a platform immunotherapy technology to treat metastatic solid tumor cancers, with its lead program demonstrating powerful clinical results in mCRPC patients with planned Q2 presentation and subsequent publication.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}